“…Promising reverse genetics systems for aMPV have been developed in recent years for A, B and C subtypes (Laconi et al., 2016; Naylor et al., 2004; Yu, Estevez, Song, Kapczynski, & Zsak, 2010), other than being an exceptional tool for the study of the virus properties (Brown et al., 2011), and can be used for the development of rationally modified aMPV vaccines (Naylor, Lupini, & Brown, 2010) or recombinant vaccines (Falchieri et al., 2013) expressing foreign genes.…”